Indications for the use of immunoglobulin therapy;Indikationen für den einsatz von immunglobulinen: Ergebnisse einer konsensuskonferenz an der medizinischen hochschule Hannover

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 31-32, 2003, Pages 1665-1669

  Heiken, Hans ^a   Schmidt, Reinhold E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; HYPERIMMUNOGLOBULINEMIA; IMMUNE DEFICIENCY; PROPHYLAXIS; SEPTIC SHOCK; TREATMENT INDICATION;

COST CONTROL; DRUG APPROVAL; DRUG COSTS; GERMANY; HUMANS; IMMUNIZATION, PASSIVE; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES;

EID: 0042235429     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41098     Document Type: Conference Paper

References (47)

1. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325: 73-80
2. The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997; 126: 319-326
3. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997; 349: 225-230
4. Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402
5. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002: CD001090
6. Azulay JP, Blin O, Pouget J et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44: 429-432
7. Barron KS, Jr. Murphy DJ, Silverman ED et al. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr 1990; 117: 638-644
8. Blanchette V, Imbach P, Andrew M et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703-707
9. Blanchette VS, Luke B, Andrew M et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-995
10. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 1996; 46: 100-103
11. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109: 1001-1004
12. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001; 345: 1870-1876
13. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000
14. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323-327
15. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137: 381-433
16. Dyck PJ, Litchy WJ, Kratz KM et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-845
17. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-593
18. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55: 1256-1262
19. Feinstein LC, Seidel K, Jocum J et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 1999; 5: 369-378
20. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789-796
21. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-1077
22. Jr. Howard JF. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998; 51: S30-S36
23. Hundt M, Manger K, Dorner T et al. Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 2000; 39: 1301-1302
24. Kumar R, Ghali A, Ekaldious AW, Mahmoud OI, AI Lumai AS. Post-transfusion purpura: case report. Ann Hematol 2001; 80: 488-491
25. Laupland KB, Dele DH. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol 1999; 20: 177-183
26. Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985; 64: 145-156
27. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124: 145-153
28. Levy J, Espanol-Boren T, Thomas C et al. Clinical spectrum of X-linked hyper-lgM syndrome. J Pediatr 1997; 131: 47-54
29. Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-449
30. Mofenson LM, Jr. Moye J, Korelitz J, Bethel J, Hirschhorn R, Nugent R The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13: 477-484
31. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-347
32. Nydegger UE. Sepsis and polyspecific intravenous immunoglobulins. J Clin Apheresis 1997; 12: 93-99
33. Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32
34. Report of an IUIS Scientific Committee. Primary Immunodeficiency Diseases. Clin Exp Immunol 1999; 118: 1-28
35. Schmidt RE, Budde U, Schafer G, Stroehmann I. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981; 2: 475-476
36. Sicherer SH, Winkelstein JA. Primary immunodeficiency diseases in adults. JAMA 1998; 279: 58-61
37. Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-1281
38. Stangel M, Hartung HP. Intravenous immunoglobulins in multiple sclerosis. Studies and mechanisms of action - an update. Nervenarzt 2002; 73: 119-124
39. Sullivan KM, Storek J, Kopecky KJ et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44-53
40. Sultan Y, Kazatchkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991; 91: 35S-39S
41. Uchino H, Yasunaga K, Akatsuka J. A cooperative clinical trial of high-dose immunoglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura. Thromb Haemost 1984; 51: 182-185
42. Van den Berg LH, Kerkhoff H, Oey PL et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59: 248-252
43. van der Meche FG, Schmitz Pl Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992; 326: 1123-1129
44. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990; 40: 209-212
45. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493
46. Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 2001; 7: 354-361
47. Winston DJ, Antin JH, Wolff SN et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 187-196